X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the Phase 3 clinical investigation of the company's PRT120 oral therapy for the treatment of patients with peanut allergy.
Lead Product(s): PRT120
Therapeutic Area: Immunology Product Name: PRT120
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 16, 2024
Details:
The PRT120-treated group achieved clinically meaningful improvements in quality of life compared with the placebo group at 12-months post-treatment (p= 0.002).
Lead Product(s): PRT120
Therapeutic Area: Immunology Product Name: PRT120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
PRT120 is an investigational oral immunotherapy with a novel high dose, rapid escalation dosing regimen for the treatment of peanut allergy. The placebo-controlled trial confirms the effectiveness of PRT120 comprising Prota's rapid escalation dosing regimen.
Lead Product(s): PRT120
Therapeutic Area: Immunology Product Name: PRT120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
